Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.44 |
| ▸ | LAP3 | P28838 | 2/20 | 0.44 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27938662 | 0.89 | LPAR3 (0.55) | SMPD1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL5689398 | 0.86 | LPAR3 (0.55) | PLA2G2CSMPD1LPAR3FDPSLPAR1 | |
| SCHEMBL25208402 | 0.84 | SMPD1 (0.51) | SMPD1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL3797731 | 0.84 | SMPD1 (0.58) | SMPD1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL3821685 | 0.84 | SMPD1 (0.58) | SMPD1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL329612 | 0.84 | SMPD1 (0.58) | SMPD1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL9484333 | 0.84 | SMPD1 (0.58) | SMPD1S1PR2S1PR1S1PR3S1PR4 | |
| Octane SCHEMBL5312682 | 0.83 | PLA2G2C (0.48) | PLA2G2CSMPD1S1PR2S1PR1S1PR3 | |
| SCHEMBL14447836 | 0.82 | LMNA (0.50) | SMPD1 | |
| SCHEMBL28017667 | 0.82 | LMNA (0.50) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) | 2002-11-21 | — | — | US | disclosed |
| US-5916884-A | CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1999-06-29 | — | — | US | disclosed |
| EP-0248062-B1 | MEDICAMENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0225608-A2 | Medicine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | PHOSPHO1, PLCG2, PPIP5K2 | PLA2G2C 33/4885SMPD1 77/4885S1PR2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.